What is EndoQuest Robotics?
EndoQuest Robotics is at the forefront of surgical innovation, having developed the ENDOQUEST Endoluminal Surgical (ELS) System. This groundbreaking robotic surgical system is the world's first of its kind, enabling therapeutic endoscopists and surgeons to perform upper and lower gastrointestinal surgeries with unprecedented minimally invasive, trans-oral, or trans-anal approaches. The platform uniquely merges the navigational flexibility of endoscopy within complex patient anatomy with robust instrumentation that empowers physicians to execute conventional two-handed surgical techniques. Beyond its primary gastrointestinal applications, the ENDOQUEST ELS System holds significant potential for a variety of other minimally invasive procedures, including appendectomies and cholecystectomies, all achievable without external incisions.
How much funding has EndoQuest Robotics raised?
EndoQuest Robotics has raised a total of $72.7M across 2 funding rounds:
Series C
$42M
Private Equity
$30.7M
Series C (2023): $42M with participation from McNair and CE Ventures
Private Equity (2025): $30.7M, investors not publicly disclosed
Key Investors in EndoQuest Robotics
McNair
McNair Interests, established in 1994, is a private investment and management firm with a diverse portfolio spanning business investment, real estate, life sciences, energy, technology, and financial services, based in Texas.
CE Ventures
CE Ventures is a venture capital fund known for providing comprehensive support to its portfolio companies, leveraging extensive Asian networks. They have a strategic investment partnership with CreditEase, a prominent Chinese FinTech entity.
What's next for EndoQuest Robotics?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for EndoQuest Robotics. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and expand commercialization efforts. The company is strategically positioned to capture a significant share of the rapidly growing surgical robotics market, particularly within the niche of endoluminal procedures. Future developments will likely focus on broadening the system's application portfolio and securing regulatory approvals in key global markets, solidifying its trajectory as a leader in advanced medical technology.
See full EndoQuest Robotics company page
